Who made PBAC's Christmas List?

A good result for a string of big name drugs that did battle with the PBAC at the November meeting - though there were repeated calls for price cuts and not everyone made it over the finish line.

It was third time lucky for Novo Nordisk which scored a recommendation for its obesity drug Wegovy in patients with established cardiovascular disease with obesity, after failing in obesity in March 2022 and severe obesity in November 2023.

AbbVie's Elahere for epithelial ovarian, fallopian tube or primary peritoneal cancer won a PBAC nod after being deferred at July's meeting pending outcomes from MSAC and the TGA. However PBAC said there now needed to be a "substantial" price reduction to reflect Elahere's moderate benefit.